Renisch B, Lauer W
Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM), Kurt-Georg-Kiesinger-Allee 3, 53175, Bonn, Deutschland,
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2014 Dec;57(12):1368-75. doi: 10.1007/s00103-014-2060-y.
An integral part of the conformity assessment process for medical devices is a clinical evaluation based on clinical data. Particularly in the case of implantable devices and products of risk class III clinical trials must be performed. Since March 2010 applications for the authorization of clinical trials as well as for the waiver of the authorization requirement must be submitted centrally in Germany to the appropriate federal authority, the Federal Institute for Drugs and Medical Devices (BfArM) or the Paul Ehrlich Institute (PEI). In addition to authorization, approval by the responsible ethics committee is also required under law in order to begin clinical testing of medical devices in Germany. In this paper, the legal framework for the clinical testing of medical devices as well as those involved and possible procedures including evaluation criteria for the initial application of a trial and subsequent amendments are presented in detail. In addition, the reporting requirements for serious adverse events (SAEs) are explained and possible consequences of the evaluation are presented. Finally, a summary of application and registration numbers for all areas of extensive experience of the BfArM as well as requests and guidance for applicants are presented.
医疗器械合格评定过程的一个不可或缺的部分是基于临床数据的临床评估。特别是对于植入式设备和III类风险产品,必须进行临床试验。自2010年3月起,在德国,临床试验授权申请以及豁免授权要求的申请必须集中提交给适当的联邦当局,即联邦药品和医疗器械研究所(BfArM)或保罗·埃利希研究所(PEI)。除了获得授权外,根据德国法律,还需要获得负责的伦理委员会的批准才能在德国开始医疗器械的临床试验。本文详细介绍了医疗器械临床试验的法律框架、相关方以及可能的程序,包括试验初始申请和后续修订的评估标准。此外,还解释了严重不良事件(SAE)的报告要求,并介绍了评估可能产生的后果。最后,总结了BfArM所有广泛经验领域的申请和注册数量,以及对申请人的要求和指导。